Skip to main content

Catalyst Calendar

Scope

Thu, Aug 13, 2026

1 updates
INKT
7:30 AM

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

First patients treated in randomized Phase 2 trial C-1300-02 were alive at Day 28, with improved oxygenation, resolution of ARDS with return to spontaneous breathing and liberation from vasopressor support Clinical recovery and biologic readouts moved in the same direction; serum and

Presentation / Abstract • Phase 2minktherapeutics.com

Thu, Aug 6, 2026

2 updates
INKT
12:00 PM

MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium

First patients treated with agenT-797 were alive and afebrile at endpoint Day 28 with improved oxygenation, infection control and removal from ventilator and vasopressor support Analysis of blood and lung fluid showed signals of infection control and biological changes associated with immune

Presentation / Abstract • Phase 2MHSRS presentation Thu, Aug 6, 2026, 11:30 AM ETminktherapeutics.com

Wed, Jun 3, 2026

1 updates
INKT
4:30 PM

MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET.

minktherapeutics.com